Pamela Garzone, Ph.D., joined Calibr as chief medical officer in May 2019, bringing decades of clinical research experience spanning large pharmaceutical companies, biotech startups and academia. She has been responsible for more than 20 successful Investigational New Drug (IND) submissions in her industrial career. Pamela most recently served as a vice president in Pfizer’s early clinical oncology group, helping to advance multiple drug candidates for cancer. Earlier, with Elan Pharmaceuticals, she held the role of senior director of clinical development, where she designed and led studies of novel compounds in healthy volunteers and patients and informed the design of multiple later-stage trials. Previous roles include consulting and working for leading drug development enterprises, including Genetics Institute (now Pfizer). She has led and managed preclinical and clinical functional lines such as toxicology, pharmacology, clinical pharmacology, translational sciences and clinical research, and has worked closely with global regulatory agencies.
Pamela earned a bachelor’s degree in pharmacy from Purdue University, and a doctorate in clinical sciences with a master’s degree in pharmacy practice from University of Pittsburgh, where she later served as assistant professor for many years. In addition to her professional work, Pamela is a passionate supporter of women in STEM and plays an active volunteer role in the nonprofit organization Women in Bio.